サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1542674

クリティカルケア治療学の世界市場

Critical Care Therapeutics

出版日
ページ情報
英文 280 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
クリティカルケア治療学の世界市場
出版日: 2024年08月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 280 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

クリティカルケア治療学の世界市場は2030年までに74億米ドルに達する見込み

2023年に50億米ドルと推定されるクリティカルケア治療学の世界市場は、2023～2030年の分析期間においてCAGR 5.6%で成長し、2030年には74億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるアルブミン薬剤クラス別は、CAGR6.9%を記録し、分析期間終了時には37億米ドルに達すると予測されます。プロトロンビン複合体濃縮薬剤クラス別セグメントの成長率は、分析期間中CAGR 4.6%と推定されます。

米国市場は13億米ドル、中国はCAGR 9.0％で成長すると予測

米国のクリティカルケア治療学市場は2023年に13億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに18億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは9.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.1%と4.4%と予測されています。欧州では、ドイツがCAGR 4.0%で成長すると予測されています。

世界のクリティカルケア治療学市場- 主要動向と促進要因のまとめ

生存の危機：クリティカルケア治療学は集中治療にどのような革命をもたらすか？

クリティカルケア治療学は、集中治療室（ICU）で生命を脅かす健康状態に直面している患者のために特別にデザインされた、さまざまな治療法を網羅しています。これらの治療には、高度な薬理学的介入、血液製剤、多臓器不全に至る可能性のある急性疾患を管理するために調整された生命維持手段が含まれます。第一の目標は、生命機能を安定させ、回復が可能になるまでそれ以上の悪化を防ぐことです。これらの治療薬は、敗血症、急性呼吸窮迫症候群（ARDS）、心不全、その他の重篤な状態の管理に不可欠です。多くの場合、血管作動薬、抗凝固薬、抗生物質、コルチコステロイド、その他の薬剤が使用され、重篤なストレス下にある臓器系をサポートします。

どのような革新がクリティカルケア治療学の分野を形成しているのでしょうか？

クリティカルケア治療学の技術革新は、ICUのような厳しい環境における患者の転帰を改善する上で極めて重要です。最近の動向には、より少ない副作用でより高い有効性を提供する、より的を絞った薬物療法の開発が含まれます。例えば、プレシジョン・メディシン・アプローチの導入により、個々の遺伝子プロファイルに基づいた治療が可能になり、重症患者の治療成績が向上する可能性があります。さらに、モノクローナル抗体や組換え蛋白質などの生物学的製剤を敗血症などの治療に用いることで、単に症状を管理するのではなく、重篤な疾患の根本的な原因に対処する新たな道が開かれました。これらの技術革新は、重篤な病態の病態生理学に関する継続的な調査によって支えられており、治療最適化のための継続的な改善基盤を提供しています。

クリティカルケア治療学の有効性に影響を与える課題とは？

大きな進歩にもかかわらず、いくつかの課題がクリティカルケア治療学の有効性に影響を与えています。治療に対する患者の反応のばらつきが大きいため、重症患者の管理が複雑になり、標準化された治療プロトコールが有効でなくなる可能性があります。また、クリティカルケア環境は、疾患の急速な進行や合併症のリスクの高さなど、独特の課題も抱えており、非常にダイナミックで即応性の高い治療戦略が必要となります。さらに、特に広域抗生物質が頻繁に使用される環境では、抗菌薬耐性のリスクが、感染症を効果的に治療する上で深刻な脅威となっています。このような課題に対処するには、最新の臨床エビデンスと治療技術に基づく集学的アプローチと治療プロトコルの継続的な適応が必要です。

クリティカルケア治療学市場の成長を促進する主な要因は？

クリティカルケア治療学市場の成長は、クリティカルケアの複雑かつ緊急なニーズを反映するいくつかの要因によって牽引されています。高齢化人口の増加による世界のヘルスケア需要の増加や、重篤な疾患につながる慢性疾患の有病率の上昇は、重要な成長促進要因です。COVID-19パンデミックのような最近の世界の健康イベントも、効果的なクリティカルケア治療学に対する需要を劇的に増大させ、重篤な急性疾患に対処できる強固な医療システムの必要性を浮き彫りにしています。新薬の発見や治療アプローチにつながる医学研究の進歩も市場の拡大に寄与しています。さらに、特に新興経済圏における世界のヘルスケア支出の増加が、ICUにおける先進的な治療ソリューションの採用を後押ししています。これらの要因が総合的にクリティカルケア治療学分野の継続的な発展と拡大を後押しし、世界の医療インフラにおける重要な役割を強調しています。

調査対象企業の例（全37件）

  • Abeona Therapeutics Inc.
  • ADMA Biologics, Inc.
  • Albumedix Ltd.
  • Asklepios Biopharmaceutical, Inc.
  • Aspen Pharmacare Holdings Ltd.
  • Baxter International Inc.
  • Bayer Healthcare AG
  • Bio Products Laboratory Ltd.
  • BioDelivery Sciences International, Inc.
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • Biotest Pharmaceuticals Corporation
  • Bristol-Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • China Biologic Products Holdings, Inc.
  • Cosmo Pharmaceuticals NV
  • CSL Behring
  • Grifols International SA
  • Kamada Ltd.
  • Kedrion Biopharma, Inc.
  • Medxbio Pte. Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novo Nordisk A/S
  • Novozymes A/S
  • Octapharma AG
  • Portola Pharmaceuticals, Inc.
  • ProMetic Life Sciences, Inc.
  • rEVO Biologics, Inc.
  • Rockwell Medical
  • Sanquin
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.
  • The Medicines Company
  • Thermo Fisher Scientific, Inc.
  • Ventria Bioscience

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP11369

Global Critical Care Therapeutics Market to Reach US$7.4 Billion by 2030

The global market for Critical Care Therapeutics estimated at US$5.0 Billion in the year 2023, is expected to reach US$7.4 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2023-2030. Albumin Drug Class, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Prothrombin Complex Concentrates Drug Class segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 9.0% CAGR

The Critical Care Therapeutics market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Critical Care Therapeutics Market - Key Trends and Drivers Summarized

At the Edge of Survival: How Are Critical Care Therapeutics Revolutionizing Intensive Care?

Critical care therapeutics encompass a range of medical treatments specifically designed for patients in intensive care units (ICUs) who are facing life-threatening health conditions. These treatments include advanced pharmacological interventions, blood products, and life-support measures tailored to manage acute illnesses that can lead to multiple organ failure. The primary goal is to stabilize vital functions and prevent further deterioration until recovery becomes feasible. These therapeutics are integral in the management of sepsis, acute respiratory distress syndrome (ARDS), cardiac failures, and other critical conditions. They often involve the use of vasoactive drugs, anticoagulants, antibiotics, corticosteroids, and other agents that support organ systems under severe stress.

What Innovations Are Shaping the Field of Critical Care Therapeutics?

Innovation in critical care therapeutics is crucial in improving patient outcomes in environments as challenging as the ICU. Recent advancements include the development of more targeted drug therapies that offer higher efficacy with fewer side effects. For instance, the introduction of precision medicine approaches allows for treatments based on individual genetic profiles, potentially enhancing the therapeutic outcomes for critically ill patients. Additionally, the use of biologics—such as monoclonal antibodies and recombinant proteins—to treat conditions like sepsis has opened new avenues for addressing the underlying causes of critical illnesses rather than just managing symptoms. These innovations are supported by ongoing research into the pathophysiology of critical conditions, providing a continuously improving basis for therapy optimization.

What Challenges Impact the Efficacy of Critical Care Therapeutics?

Despite significant advancements, several challenges impact the efficacy of critical care therapeutics. The high variability in patient responses to treatments can complicate the management of critical illnesses, making standardized treatment protocols less effective. The critical care environment also presents unique challenges, such as the rapid progression of diseases and the high risk of complications, which require exceptionally dynamic and responsive treatment strategies. Moreover, the risk of antimicrobial resistance, particularly in settings where broad-spectrum antibiotics are frequently used, poses a serious threat to treating infections effectively. Addressing these challenges requires a multidisciplinary approach and continuous adaptation of treatment protocols based on the latest clinical evidence and therapeutic technologies.

What Are the Key Drivers Propelling the Growth of the Critical Care Therapeutics Market?

The growth in the critical care therapeutics market is driven by several factors, reflecting the complex and urgent nature of critical care needs. Increasing global healthcare demands due to a rising aging population and higher prevalence of chronic diseases that can lead to critical illness are significant growth drivers. The recent global health events, such as the COVID-19 pandemic, have also dramatically increased the demand for effective critical care therapeutics, highlighting the need for robust health systems capable of managing severe acute conditions. Advances in medical research that lead to new drug discoveries and therapeutic approaches contribute to market expansion as well. Furthermore, increased healthcare spending worldwide, especially in emerging economies, supports the adoption of advanced therapeutic solutions in ICUs. These factors collectively fuel the ongoing development and expansion of the critical care therapeutics sector, underscoring its vital role in global health infrastructure.

Select Competitors (Total 37 Featured) -

  • Abeona Therapeutics Inc.
  • ADMA Biologics, Inc.
  • Albumedix Ltd.
  • Asklepios Biopharmaceutical, Inc.
  • Aspen Pharmacare Holdings Ltd.
  • Baxter International Inc.
  • Bayer Healthcare AG
  • Bio Products Laboratory Ltd.
  • BioDelivery Sciences International, Inc.
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • Biotest Pharmaceuticals Corporation
  • Bristol-Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • China Biologic Products Holdings, Inc.
  • Cosmo Pharmaceuticals NV
  • CSL Behring
  • Grifols International SA
  • Kamada Ltd.
  • Kedrion Biopharma, Inc.
  • Medxbio Pte. Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novo Nordisk A/S
  • Novozymes A/S
  • Octapharma AG
  • Portola Pharmaceuticals, Inc.
  • ProMetic Life Sciences, Inc.
  • rEVO Biologics, Inc.
  • Rockwell Medical
  • Sanquin
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.
  • The Medicines Company
  • Thermo Fisher Scientific, Inc.
  • Ventria Bioscience

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Critical Care Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Chronic Diseases Drives Demand for Critical Care Therapeutics
    • Advancements in Biotechnology Propel Development of Innovative Critical Care Drugs
    • Increased Investment in Healthcare Infrastructure Supports Critical Care Therapeutic Availability
    • Growing Geriatric Population Bolsters Market for Age-Specific Therapeutic Solutions
    • Rise in Healthcare Expenditure Worldwide Sustains Growth in Therapeutic Development
    • Demand for Multifunctional Drugs Amplifies Development of Combination Therapies
    • Technological Advances in Drug Delivery Systems Enhance Critical Care Management
    • Health Insurance Coverage Influence Therapeutic Adoption
    • Expansion of Emergency Care Units Worldwide Drives Need for Advanced Therapeutics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Critical Care Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Albumin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Albumin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Albumin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Prothrombin Complex Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Prothrombin Complex Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Prothrombin Complex Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Antithrombin Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Antithrombin Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Antithrombin Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Deep Vein Thrombosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Pulmonary Embolism (PE) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Pulmonary Embolism (PE) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Pulmonary Embolism (PE) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Critical Care Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Critical Care Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • FRANCE
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Critical Care Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • INDIA
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Critical Care Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Critical Care Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • AFRICA
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION